Difficulty: Medium
Average Score: 81%
Practice
Pancuronium differs from tubocurarine in that
Correct answer
C
Rationale
In this question about the differences between Pancuronium and Tubocurarine in the context of central and peripheral nervous system drugs, the correct answer is C) It can cause a rise in BP on rapid I.V. injection.
Pancuronium is a non-depolarizing neuromuscular blocking agent, unlike tubocurarine which is a depolarizing blocker. The rapid intravenous administration of Pancuronium can lead to a transient increase in blood pressure due to its vagolytic effects. This is because Pancuronium has a quaternary ammonium structure that can stimulate ganglionic nicotinic receptors, causing an increase in sympathetic tone and subsequent rise in blood pressure.
The other options are incorrect because:
A) Pancuronium is a non-depolarizing blocker, not a depolarizing one.
B) Neostigmine is able to reverse the effects of Pancuronium by competitively inhibiting acetylcholinesterase, leading to an increase in acetylcholine at the neuromuscular junction.
D) Unlike some other neuromuscular blocking agents like atracurium, Pancuronium does not cause significant histamine release, making this statement inaccurate.
Understanding the differences between these drugs is crucial in clinical practice, especially in anesthesia and critical care settings where neuromuscular blocking agents are commonly used to facilitate intubation or surgery. Knowing the specific characteristics of each drug helps healthcare providers make informed decisions regarding drug selection, dosing, and management of potential side effects.
Pancuronium is a non-depolarizing neuromuscular blocking agent, unlike tubocurarine which is a depolarizing blocker. The rapid intravenous administration of Pancuronium can lead to a transient increase in blood pressure due to its vagolytic effects. This is because Pancuronium has a quaternary ammonium structure that can stimulate ganglionic nicotinic receptors, causing an increase in sympathetic tone and subsequent rise in blood pressure.
The other options are incorrect because:
A) Pancuronium is a non-depolarizing blocker, not a depolarizing one.
B) Neostigmine is able to reverse the effects of Pancuronium by competitively inhibiting acetylcholinesterase, leading to an increase in acetylcholine at the neuromuscular junction.
D) Unlike some other neuromuscular blocking agents like atracurium, Pancuronium does not cause significant histamine release, making this statement inaccurate.
Understanding the differences between these drugs is crucial in clinical practice, especially in anesthesia and critical care settings where neuromuscular blocking agents are commonly used to facilitate intubation or surgery. Knowing the specific characteristics of each drug helps healthcare providers make informed decisions regarding drug selection, dosing, and management of potential side effects.